NCT07026123Not yet recruiting
A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China
Source: ClinicalTrials.gov · Last updated 18 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is designed to evaluate the real world efficacy and safety of the liposomal irinotecan (Onivyde®)-based treatment scheme in Chinese patients with locally advanced or metastatic pancreatic cancer, and to compare the efficacy with that of the whole pancreatic cancer population who did not receive relevant treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 10 Jun 2025
- Start date
- 1 Jul 2025
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- RenJi Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT07026123
What you commit to
- Study type: Observational
- Planned participants: 40
- From 1 Jul 2025 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Confirm pregnant or lactating women.
- The patient's clinical data is not available.
- The researchers determined that they were not suitable for inclusion in the study due to other circumstances.
Who the study is looking for
- Age ≥ 18 years old.
- Patients with locally advanced or metastatic PDAC diagnosed by pathology.
- Patients who received at least one cycle of Nal-IRI (Onivyde®）+ 5-FU/LV treatment.
- Patients who have progressed in treatment with gemcitabine or gemcitabine containing regimens in the past.
- The patient voluntarily participates in the study and signs an informed consent form.
- Age ≥ 18 years old.
- Patients with locally advanced or metastatic PDAC diagnosed by pathology.
- Not received Nal IRI (Onivyde®)+ 5-FU/LV treatment in the past.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiao Tong University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.